- Home
- RNGR vs URGN Comparison
RNGR vs URGN Comparison
Compare RNGR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNGR
- URGN
- Stock Information
- Founded
- RNGR 2017
- URGN 2004
- Country
- RNGR United States
- URGN United States
- Employees
- RNGR N/A
- URGN N/A
- Industry
- RNGR Oilfield Services/Equipment
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- RNGR Energy
- URGN Health Care
- Exchange
- RNGR Nasdaq
- URGN Nasdaq
- Market Cap
- RNGR 388.4M
- URGN 465.9M
- IPO Year
- RNGR 2017
- URGN 2017
- Fundamental
- Price
- RNGR $14.37
- URGN $10.63
- Analyst Decision
- RNGR Hold
- URGN Strong Buy
- Analyst Count
- RNGR 2
- URGN 6
- Target Price
- RNGR $12.50
- URGN $40.75
- AVG Volume (30 Days)
- RNGR 111.2K
- URGN 419.1K
- Earning Date
- RNGR 05-06-2025
- URGN 03-10-2025
- Dividend Yield
- RNGR 1.69%
- URGN N/A
- EPS Growth
- RNGR N/A
- URGN N/A
- EPS
- RNGR 0.81
- URGN N/A
- Revenue
- RNGR $571,100,000.00
- URGN $90,398,000.00
- Revenue This Year
- RNGR $11.70
- URGN $43.60
- Revenue Next Year
- RNGR N/A
- URGN $103.77
- P/E Ratio
- RNGR $17.52
- URGN N/A
- Revenue Growth
- RNGR N/A
- URGN 9.29
- 52 Week Low
- RNGR $9.27
- URGN $9.03
- 52 Week High
- RNGR $18.45
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- RNGR 40.32
- URGN 44.41
- Support Level
- RNGR $13.77
- URGN $11.12
- Resistance Level
- RNGR $15.18
- URGN $11.91
- Average True Range (ATR)
- RNGR 0.49
- URGN 0.56
- MACD
- RNGR 0.07
- URGN -0.07
- Stochastic Oscillator
- RNGR 42.55
- URGN 3.87
About RNGR Ranger Energy Services Inc.
Ranger Energy Services Inc is a provider of onshore high specification (high-spec) well service rigs, wireline services, and additional processing solutions and ancillary services in the United States. It offers a range of well site services to U.S. exploration and production (E&P) companies that are fundamental to establishing and enhancing the flow of oil and natural gas throughout the productive life of a well. The segments of the group are High Specification Rigs, Wireline Services and Processing Solutions and Ancillary Services, of which key revenue is derived from High Specification Rigs segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.